Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial

MLA

Andrew Briggs, et al. “Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Following Autologous Stem Cell Transplant: A Cost-Effectiveness Analysis Updated with 5-Year Follow-up Data from the Pivotal Trial.” Journal of Clinical Oncology, vol. 34, Mar. 2016, p. 19. EBSCOhost, https://doi.org/10.1200/jco.2016.34.7_suppl.19.

APA

Andrew Briggs, Peter Sajosi, Jeremy Teasell, Vijayveer Bonthapally, Beth Woods, Akshara Richhariya, James Eaton, Andreas Engstrom, Eugene Benson, Chris Parker, Ross Selby, Esprit Ma, & Gemma Kay. (2016). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial. Journal of Clinical Oncology, 34, 19. https://doi.org/10.1200/jco.2016.34.7_suppl.19

Chicago

Andrew Briggs, Peter Sajosi, Jeremy Teasell, Vijayveer Bonthapally, Beth Woods, Akshara Richhariya, James Eaton, et al. 2016. “Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma Following Autologous Stem Cell Transplant: A Cost-Effectiveness Analysis Updated with 5-Year Follow-up Data from the Pivotal Trial.” Journal of Clinical Oncology 34 (March): 19. doi:10.1200/jco.2016.34.7_suppl.19.